- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02005692
A Pilot Study to Assess the DynaSense System
August 10, 2014 updated by: Leaf Healthcare, Inc.
The study is designed to test the DynaSense system, which is a patient movement and orientation monitoring system. The study is intended to determine that:
- the DynaSense system identifies patients that are not turning adequately on their own and therefore require caregiver-assisted turns.
- the DynaSense system identifies patients that are turning adequately on their own and therefore do not require a caregiver-assisted turn.
- the DynaSense system helps ensure compliance with an institution's established patient turning protocol.
Study Overview
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Mountain View, California, United States, 94040
- El Camino Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult male or female 18 to 110 years of age;
- Inpatient currently on the unit and expected to remain for at least 12 hours;
- Able and willing to comply with the study procedures;
- Subject (or his/her agent) is able to read, understand, and provide Informed Consent in the English language.
Exclusion Criteria:
Subject is a female subject under the age of 60 who is pregnant, planning on becoming pregnant, or is currently breastfeeding.
- Any woman under the age of 60, must have a negative urine pregnancy test prior to being enrolled in the study; OR
- Be postmenopausal for at least 2 years, OR
- have had a bilateral tubal ligations, OR
- have had a bilateral oophorectomy, OR
- have had a hysterectomy.
- Subjects with a known tape allergy or sensitivity to EKG leads or similar types of adhesives used in common medical products.
- Subjects who cannot have the patient sensor applied on the surface of the patient's anterior torso.
- Subjects who have a pacemaker or implantable cardiovascular-defibrillator (ICD).
- Subjects with dementia, Alzheimer's disease or other mental disabilities and incapacitation that would prevent the subject from providing written informed consent. If the subject is unable to provide informed consent due to mental incapacity, then the subject's Durable Power of Attorney may provide informed consent and sign the informed consent on behalf of the subject.
- Subjects who refuse to have an area of hair on their chest be clipped or shaved, if needed for patient sensor adhesion.
- Subjects, who in the opinion of the Principal Investigator, are at increased risk by participating in the clinical study.
- Subjects who have participated in another clinical study within the past 30 days or are currently participating in another clinical study at the time of screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DynaSense sensor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Primary Endpoint
Time Frame: Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.
|
The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.
|
Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE.
|
Turn Protocol Compliance
Time Frame: Subjects will be followed for the length of hospital stay which is expected to average 5 days.
|
The primary clinical efficacy endpoint is to assess the change in turning protocol compliance after implementation of the DynaSense system.
|
Subjects will be followed for the length of hospital stay which is expected to average 5 days.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michelle Pezzani, MD, El Camino Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (ACTUAL)
February 1, 2014
Study Completion (ACTUAL)
February 1, 2014
Study Registration Dates
First Submitted
November 27, 2013
First Submitted That Met QC Criteria
December 4, 2013
First Posted (ESTIMATE)
December 9, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
August 13, 2014
Last Update Submitted That Met QC Criteria
August 10, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CM-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pressure Ulcers
-
KLOX Technologies Inc.CompletedPressure Ulcers Stage II | Pressure Ulcers Stage IIICanada
-
EmoledRecruitingPressure Ulcer | Pressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure SoreItaly
-
ULURU Inc.United States Department of DefenseRecruitingPressure Ulcers Stage II | Pressure Ulcers Stage III | Pressure Ulcer, Stage IVUnited States
-
Signorini Medicale S.r.l.Opera CRO, a TIGERMED Group CompanyNot yet recruitingBurn Wound | Pressure Ulcers Stage II | Pressure Ulcers Stage IIIRomania
-
Charite University, Berlin, GermanyCompleted
-
Central Arkansas Veterans Healthcare SystemAbbottTerminatedPressure UlcersUnited States
-
Hill-RomCompletedPressure UlcersUnited States
-
Bruin Biometrics, LLCCompleted
-
Molnlycke Health Care ABCompleted
Clinical Trials on DynaSense sensor
-
Northwestern UniversityCompletedAtopic Dermatitis | Healthy Adults | Wearables | Sweat Sensor | Gas SensorUnited States
-
Medtronic DiabetesCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Nantes University HospitalCompletedMultiple SclerosisFrance
-
Proteus Digital Health, Inc.CompletedEssential Hypertension
-
Medtronic DiabetesCompletedDiabetesUnited States
-
Goalspal LLCRecruitingParkinson DiseaseUnited States
-
Fredrik IredahlPrimary Health Care Center, Department of Health Medicine and Caring Sciences...TerminatedWound | Ulcer, Leg | Exuding WoundsSweden
-
Centre Hospitalier Universitaire DijonCompletedDiabetes | Old Age | Institutionalized in EHPAD (French Nursing Home) | Hypoglycemic SyndromeFrance
-
Tampere University HospitalTampere University; Tampere University of TechnologyUnknownCardiovascular Diseases | Abdominal Aortic AneurysmFinland